|
1
|
Normalization of hemoglobin level in patients with chronic kidney disease and anemia.
|
N Engl J Med
|
2006
|
10.65
|
|
2
|
Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis.
|
N Engl J Med
|
2004
|
6.52
|
|
3
|
Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure.
|
Nephrol Dial Transplant
|
2004
|
4.27
|
|
4
|
Health-related quality of life as a predictor of mortality and hospitalization: the Dialysis Outcomes and Practice Patterns Study (DOPPS).
|
Kidney Int
|
2003
|
3.90
|
|
5
|
Pure red-cell aplasia and epoetin therapy.
|
N Engl J Med
|
2004
|
3.49
|
|
6
|
The burden of kidney disease: improving global outcomes.
|
Kidney Int
|
2004
|
2.94
|
|
7
|
Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial.
|
J Am Soc Nephrol
|
2004
|
2.47
|
|
8
|
Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy.
|
Ann Intern Med
|
2003
|
2.47
|
|
9
|
Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial.
|
J Am Soc Nephrol
|
2005
|
2.25
|
|
10
|
Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP).
|
Nephrol Dial Transplant
|
2008
|
2.24
|
|
11
|
Latest US KDOQI Anaemia Guidelines update--what are the implications for Europe?
|
Nephrol Dial Transplant
|
2007
|
2.12
|
|
12
|
A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis.
|
Am J Kidney Dis
|
2008
|
2.02
|
|
13
|
Peginesatide in patients with anemia undergoing hemodialysis.
|
N Engl J Med
|
2013
|
2.00
|
|
14
|
Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS).
|
Am J Kidney Dis
|
2004
|
1.93
|
|
15
|
Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options.
|
Clin J Am Soc Nephrol
|
2011
|
1.84
|
|
16
|
Mortality and hospitalization in haemodialysis patients in five European countries: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS).
|
Nephrol Dial Transplant
|
2004
|
1.83
|
|
17
|
Association of predialysis serum bicarbonate levels with risk of mortality and hospitalization in the Dialysis Outcomes and Practice Patterns Study (DOPPS).
|
Am J Kidney Dis
|
2004
|
1.81
|
|
18
|
Mini-peritoneal equilibration test: A simple and fast method to assess free water and small solute transport across the peritoneal membrane.
|
Kidney Int
|
2005
|
1.80
|
|
19
|
The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism.
|
Clin J Am Soc Nephrol
|
2008
|
1.76
|
|
20
|
Light chain deposition disease with renal involvement: clinical characteristics and prognostic factors.
|
Am J Kidney Dis
|
2003
|
1.73
|
|
21
|
Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy.
|
J Am Soc Nephrol
|
2010
|
1.70
|
|
22
|
Erythropoiesis-stimulating agents and antibody-mediated pure red-cell aplasia: here are we now and where do we go from here?
|
Nephrol Dial Transplant
|
2004
|
1.59
|
|
23
|
Effects of ionized sodium concentrations on ultrafiltration rate in peritoneal dialysis using lactate and lactate/bicarbonate solutions.
|
Perit Dial Int
|
2009
|
1.57
|
|
24
|
Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy.
|
Am J Kidney Dis
|
2005
|
1.54
|
|
25
|
Safety issues related to erythropoiesis-stimulating agents used to treat anemia in patients with chronic kidney disease.
|
Expert Opin Drug Saf
|
2012
|
1.51
|
|
26
|
Improving outcomes for dialysis patients in the international Dialysis Outcomes and Practice Patterns Study.
|
Clin J Am Soc Nephrol
|
2006
|
1.47
|
|
27
|
Facility-level interpatient hemoglobin variability in hemodialysis centers participating in the Dialysis Outcomes and Practice Patterns Study (DOPPS): Associations with mortality, patient characteristics, and facility practices.
|
Am J Kidney Dis
|
2011
|
1.45
|
|
28
|
Current Evidence in Haemodiafiltration.
|
Blood Purif
|
2015
|
1.41
|
|
29
|
IgA nephritis: ACE inhibitors, steroids, both or neither?
|
Nephrol Dial Transplant
|
2006
|
1.41
|
|
30
|
Stopping a medical research project for financial reasons.
|
Nephrol Dial Transplant
|
2003
|
1.40
|
|
31
|
Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.
|
Clin J Am Soc Nephrol
|
2007
|
1.40
|
|
32
|
Erythropoietic response to erythropoiesis-stimulating agents and outcome: should we give up the haemoglobin target approach?
|
Nephrol Dial Transplant
|
2011
|
1.39
|
|
33
|
Use of phosphate-binding agents is associated with a lower risk of mortality.
|
Kidney Int
|
2013
|
1.35
|
|
34
|
C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trial.
|
Clin J Am Soc Nephrol
|
2008
|
1.34
|
|
35
|
Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project.
|
Blood
|
2005
|
1.30
|
|
36
|
The changing epidemiology of hepatitis C virus (HCV) infection in haemodialysis: European multicentre study.
|
Nephrol Dial Transplant
|
2004
|
1.18
|
|
37
|
Left ventricular geometry predicts cardiovascular outcomes associated with anemia correction in CKD.
|
J Am Soc Nephrol
|
2009
|
1.13
|
|
38
|
The epidemiology of end-stage renal disease in Iran in an international perspective.
|
Nephrol Dial Transplant
|
2002
|
1.12
|
|
39
|
Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guidelines: a European Renal Best Practice (ERBP) commentary statement.
|
Nephrol Dial Transplant
|
2010
|
1.11
|
|
40
|
Predictors of outcome in Henoch-Schönlein nephritis in children and adults.
|
Am J Kidney Dis
|
2006
|
1.11
|
|
41
|
Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study.
|
Nephrol Dial Transplant
|
2008
|
1.10
|
|
42
|
Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial.
|
Nephrol Dial Transplant
|
2010
|
1.10
|
|
43
|
The quality of dialysis water.
|
Nephrol Dial Transplant
|
2003
|
1.10
|
|
44
|
Kidney and liver involvement in monoclonal light chain disorders.
|
Semin Nephrol
|
2002
|
1.09
|
|
45
|
What we know about oxidative stress in patients with chronic kidney disease on dialysis--clinical effects, potential treatment, and prevention.
|
Semin Dial
|
2011
|
1.07
|
|
46
|
Increasing home based dialysis therapies to tackle dialysis burden around the world: a position statement on dialysis economics from the 2nd Congress of the International Society for Hemodialysis.
|
Nephrology (Carlton)
|
2011
|
1.06
|
|
47
|
Biosimilars and regulatory authorities.
|
Nephron Clin Pract
|
2010
|
1.06
|
|
48
|
Hemodialysis vascular access training and practices are key to improved access outcomes.
|
Am J Kidney Dis
|
2010
|
1.03
|
|
49
|
Variation in intravenous iron use internationally and over time: the Dialysis Outcomes and Practice Patterns Study (DOPPS).
|
Nephrol Dial Transplant
|
2013
|
1.01
|
|
50
|
Inflammation and resistance to treatment with recombinant human erythropoietin.
|
J Ren Nutr
|
2005
|
1.01
|
|
51
|
The regulatory framework of biosimilars in the European Union.
|
Drug Discov Today
|
2011
|
0.98
|
|
52
|
Sodium balance in hemodialysis therapy.
|
Semin Dial
|
2003
|
0.97
|
|
53
|
The role of blood volume reduction in the genesis of intradialytic hypotension.
|
Am J Kidney Dis
|
2002
|
0.95
|
|
54
|
Current management of secondary hyperparathyroidism: a multicenter observational study (COSMOS).
|
J Nephrol
|
2008
|
0.95
|
|
55
|
IgA nephropathy with severe chronic renal failure: a randomized controlled trial of corticosteroids and azathioprine.
|
J Nephrol
|
2013
|
0.94
|
|
56
|
Linking drugs to obscure illnesses: lessons from pure red cell aplasia, nephrogenic systemic fibrosis, and Reye's syndrome. a report from the Southern Network on Adverse Reactions (SONAR).
|
J Gen Intern Med
|
2012
|
0.94
|
|
57
|
C.E.R.A. once every 4 weeks corrects anaemia and maintains haemoglobin in patients with chronic kidney disease not on dialysis.
|
Nephrol Dial Transplant
|
2011
|
0.93
|
|
58
|
International Study of Health Care Organization and Financing for renal replacement therapy in Italy: an evolving reality.
|
Int J Health Care Finance Econ
|
2007
|
0.93
|
|
59
|
COSMOS: the dialysis scenario of CKD-MBD in Europe.
|
Nephrol Dial Transplant
|
2012
|
0.92
|
|
60
|
Overfill of peritoneal dialysis bags as a cause of underestimation of ultrafiltration failure.
|
Perit Dial Int
|
2006
|
0.92
|
|
61
|
Sodium removal and sodium concentration during peritoneal dialysis: effects of three methods of sodium measurement.
|
Nephrol Dial Transplant
|
2004
|
0.91
|
|
62
|
Anaemia management in non-dialysis chronic kidney disease (CKD) patients: a multicentre prospective study in renal clinics.
|
Nephrol Dial Transplant
|
2013
|
0.90
|
|
63
|
Darbepoetin alfa impact on health status in diabetes patients with kidney disease: a randomized trial.
|
Clin J Am Soc Nephrol
|
2011
|
0.90
|
|
64
|
High-flux versus low-flux membranes for end-stage kidney disease.
|
Cochrane Database Syst Rev
|
2012
|
0.90
|
|
65
|
Convection versus diffusion in dialysis: an Italian prospective multicentre study.
|
Nephrol Dial Transplant
|
2003
|
0.89
|
|
66
|
Dialysis adequacy today: a European perspective.
|
Nephrol Dial Transplant
|
2012
|
0.89
|
|
67
|
Influence of body mass index on the association of weight changes with mortality in hemodialysis patients.
|
Clin J Am Soc Nephrol
|
2013
|
0.89
|
|
68
|
Prospective multicenter study of HX575 (biosimilar epoetin-α) in patients with chronic kidney disease applying a target hemoglobin of 10--12 g/dl.
|
Clin Nephrol
|
2012
|
0.89
|
|
69
|
Cinacalcet for cardiovascular disease in patients undergoing dialysis.
|
N Engl J Med
|
2013
|
0.89
|
|
70
|
Hypertension in dialysis: pathophysiology and treatment.
|
J Nephrol
|
2002
|
0.88
|
|
71
|
Clinical evidence on hemodiafiltration: a systematic review and a meta-analysis.
|
Semin Dial
|
2014
|
0.88
|
|
72
|
Dialysate composition.
|
Contrib Nephrol
|
2008
|
0.87
|
|
73
|
European best practice quo vadis? From European Best Practice Guidelines (EBPG) to European Renal Best Practice (ERBP).
|
Nephrol Dial Transplant
|
2008
|
0.86
|
|
74
|
Anemia in chronic kidney disease patients: treatment recommendations and emerging therapies.
|
Expert Rev Hematol
|
2014
|
0.86
|
|
75
|
Are natriuretic peptides a reliable marker for mortality in ESRD patients?
|
Nephrol Dial Transplant
|
2009
|
0.85
|
|
76
|
Impact of irbesartan, blood pressure control, and proteinuria on renal outcomes in the Irbesartan Diabetic Nephropathy Trial.
|
Kidney Int Suppl
|
2004
|
0.85
|
|
77
|
Automatic adaptive system dialysis for hemodialysis-associated hypotension and intolerance: a noncontrolled multicenter trial.
|
Am J Kidney Dis
|
2011
|
0.84
|
|
78
|
Long-term outcome in hemodialysis: morbidity and mortality.
|
J Nephrol
|
2004
|
0.84
|
|
79
|
Anemia management in patients on peritoneal dialysis.
|
Contrib Nephrol
|
2012
|
0.83
|
|
80
|
Chronic kidney disease-associated anemia: new remedies.
|
Curr Opin Investig Drugs
|
2010
|
0.83
|
|
81
|
Can immunosuppressive therapy be useful in IgA nephropathy when the 'Point of No Return' has already been exceeded?
|
Nephron
|
2002
|
0.83
|
|
82
|
Kidney and liver involvement in cryoglobulinemia.
|
Semin Nephrol
|
2002
|
0.83
|
|
83
|
ACE inhibitors and angiotensin II receptor blockers in IgA nephropathy with mild proteinuria: the ACEARB study.
|
J Nephrol
|
2006
|
0.83
|
|
84
|
Transport of peritoneal membrane assessed before and after the start of peritoneal dialysis.
|
Nephrol Dial Transplant
|
2009
|
0.83
|
|
85
|
Geriatric nephrology.
|
J Nephrol
|
2010
|
0.82
|
|
86
|
Effectiveness of sodium and conductivity kinetic models in predicting end-dialysis plasma water sodium concentration: preliminary results of a single-center experience.
|
Hemodial Int
|
2007
|
0.82
|
|
87
|
CKD patients: the dilemma of serum PTH levels.
|
Nephron Clin Pract
|
2010
|
0.81
|
|
88
|
Renal anemia: comparing current Eastern and Western European management practice (ORAMA).
|
Ren Fail
|
2008
|
0.81
|
|
89
|
Sodium removal during pre-dilution haemofiltration.
|
Nephrol Dial Transplant
|
2003
|
0.81
|
|
90
|
Peginesatide as a new approach for treating anemia of CKD patient: is it like a falling star?
|
Expert Opin Pharmacother
|
2013
|
0.81
|
|
91
|
Pure red cell aplasia secondary to treatment with erythropoietin.
|
Artif Organs
|
2003
|
0.80
|
|
92
|
Autosomal dominant polycystic kidney disease and mTOR inhibitors: the narrow road between hope and disappointment.
|
Nephrol Dial Transplant
|
2010
|
0.80
|
|
93
|
Effect of synthetic vitamin E-bonded membrane on responsiveness to erythropoiesis-stimulating agents in hemodialysis patients: a pilot study.
|
Nephron Clin Pract
|
2010
|
0.80
|
|
94
|
A new initiative in nephrology: 'Kidney disease: improving global outcomes'.
|
Contrib Nephrol
|
2005
|
0.79
|
|
95
|
Novel techniques and innovation in blood purification: a clinical update from Kidney Disease: Improving Global Outcomes.
|
Kidney Int
|
2013
|
0.79
|
|
96
|
Epidemiology and prevention of cardiovascular complication in chronic kidney disease patients.
|
Semin Nephrol
|
2004
|
0.79
|
|
97
|
The QUEST initiative anemia study in transplant patients: rationale and study protocol.
|
J Nephrol
|
2007
|
0.78
|
|
98
|
Methoxypolyethylene glycol-epoetin beta for the treatment of anemia associated with chronic kidney disease.
|
Drugs Today (Barc)
|
2008
|
0.78
|
|
99
|
Recombinant human epoetin beta in the treatment of renal anemia.
|
Ther Clin Risk Manag
|
2007
|
0.78
|
|
100
|
The QUEST initiative anemia study in ESRD: rationale and study protocol.
|
J Nephrol
|
2007
|
0.78
|
|
101
|
Efficacy and tolerability of manidipine in the treatment of hypertension in patients with non-diabetic chronic kidney disease without glomerular disease. Prospective, randomized, double-blind study of parallel groups in comparison with enalapril.
|
J Nephrol
|
2004
|
0.77
|
|
102
|
The First European Renal Association-European Dialysis and Transplant Association CKD Anaemia Physician Behaviours Survey: key findings.
|
J Nephrol
|
2008
|
0.77
|
|
103
|
Ethical issues in the elderly with renal disease.
|
Clin Geriatr Med
|
2009
|
0.77
|
|
104
|
Comparison of hemodialysis, hemodiafiltration, and hemofiltration: systematic review or systematic error?
|
Am J Kidney Dis
|
2005
|
0.77
|
|
105
|
Responsiveness to erythropoiesis-stimulating agents in chronic kidney disease: does geography matter?
|
Drugs
|
2014
|
0.77
|
|
106
|
What can we learn from a statistically inconclusive trial? Consensus conference on the EVOLVE study results.
|
G Ital Nefrol
|
2014
|
0.77
|
|
107
|
New treatment approaches in chronic kidney disease-associated anaemia.
|
Expert Opin Biol Ther
|
2014
|
0.76
|
|
108
|
Clinical validation of glucose pump test (GPT) compared with ultrasound dilution technology in arteriovenous graft surveillance.
|
Nephrol Dial Transplant
|
2004
|
0.76
|
|
109
|
Pathochemical toxicity of perfluorocarbon-5070, a liquid test performance fluid previously used in dialyzer manufacturing, confirmed in animal experiment.
|
J Am Soc Nephrol
|
2005
|
0.76
|
|
110
|
Effect of dialysis dose and membrane flux in maintenance hemodialysis.
|
N Engl J Med
|
2003
|
0.76
|
|
111
|
Geographical variability of patient characteristics and treatment patterns affect outcomes for incident hemodialysis patients.
|
J Nephrol
|
2013
|
0.76
|
|
112
|
A Randomized Trial on Health-Related Patient Satisfaction Level with High-Efficiency Online Hemodiafiltration versus High-Flux Dialysis.
|
Blood Purif
|
2015
|
0.76
|
|
113
|
Haemodiafiltration at Higher Volumes and Patient Survival.
|
Contrib Nephrol
|
2016
|
0.75
|
|
114
|
Darbepoetin alfa and chronic kidney disease.
|
N Engl J Med
|
2010
|
0.75
|
|
115
|
Hematocrit and prohepcidin: causation or simply association?
|
Blood Purif
|
2006
|
0.75
|
|
116
|
Peginesatide for maintenance treatment of anemia in hemodialysis and nondialysis patients previously treated with darbepoetin alfa.
|
Clin J Am Soc Nephrol
|
2012
|
0.75
|
|
117
|
Erythropoietin in kidney disease and type 2 diabetes.
|
N Engl J Med
|
2011
|
0.75
|
|
118
|
Letter regarding article by Solomon et al, "Cardiac Angiography in REnally Impaired Patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease".
|
Circulation
|
2008
|
0.75
|
|
119
|
Prospective randomized pilot study on the effects of two synthetic high-flux dialyzers on dialysis patient anemia.
|
Int J Artif Organs
|
2012
|
0.75
|
|
120
|
Therapy of anemia: is it only a number to reach or are there other variables to control?
|
Blood Purif
|
2013
|
0.75
|
|
121
|
[The use of drugs in chronic renal insufficiency: primum non nocere! (First do not harm!). The paradigmatic cases of azathioprine, metformin and denosumab].
|
G Ital Nefrol
|
2016
|
0.75
|
|
122
|
[Nephrologist's behaviours and perceptions on sideropenic anemia's diagnosis and treatment for conservative phase nephropatic patient intolerant or not responding to oral iron therapy].
|
G Ital Nefrol
|
2014
|
0.75
|
|
123
|
[KDIGO guidelines for the diagnosis and treatment of chronic kidney disease mineral and bone disorder: what's new?].
|
G Ital Nefrol
|
2010
|
0.75
|
|
124
|
Uraemic toxins versus volume and water as the major factor that matters with dialysis.
|
Nephrol Dial Transplant
|
2012
|
0.75
|
|
125
|
Membrane characteristics.
|
Contrib Nephrol
|
2008
|
0.75
|
|
126
|
Ethical considerations in nephro-geriatrics.
|
J Nephrol
|
2012
|
0.75
|
|
127
|
The new Research Agenda and Public Health interface: a framework for improving care.
|
Nephrol Dial Transplant
|
2012
|
0.75
|
|
128
|
New Strategies for Anaemia Management in Chronic Kidney Disease.
|
Contrib Nephrol
|
2016
|
0.75
|
|
129
|
Dyslipidemia in chronic kidney disease: randomized controlled trial of colestilan versus simvastatin in dialysis patients.
|
Clin Nephrol
|
2014
|
0.75
|
|
130
|
The contribution of early nephropathy to cardiovascular risk.
|
Cardiol Clin
|
2010
|
0.75
|
|
131
|
Randomized, Double-Blind, Placebo-Controlled, Withdrawal Study of Colestilan after Dose Titration in Chronic Kidney Disease Dialysis Patients with Hyperphosphatemia.
|
Nephron
|
2015
|
0.75
|
|
132
|
[Italian adaptation of the European Renal Best Practice (ERBP) guideline on kidney donor and recipient evaluation and perioperative care].
|
G Ital Nefrol
|
2014
|
0.75
|
|
133
|
[Lights and shadows on single and dual RAAS blockade].
|
G Ital Nefrol
|
2010
|
0.75
|
|
134
|
Introduction. The role of on-line monitoring of dialysate conductivity to ensure adequate delivery of dialysis dose.
|
Kidney Int Suppl
|
2004
|
0.75
|
|
135
|
The relevance of convection in clinical practice: a critical review of the literature.
|
Hemodial Int
|
2006
|
0.75
|
|
136
|
New erythropoiesis-stimulating agents: how innovative are they?
|
Contrib Nephrol
|
2008
|
0.75
|
|
137
|
Relationship between urea clearance and ionic dialysance determined using a single-step conductivity profile.
|
Kidney Int
|
2005
|
0.75
|
|
138
|
Introduction and context: the past, present and future of CKD research.
|
Nephrol Dial Transplant
|
2012
|
0.75
|
|
139
|
[Interview with Prof. Francesco Locatelli: an international nephrologist of all seasons by Timio Mario].
|
G Ital Nefrol
|
2011
|
0.75
|
|
140
|
How will the results of the HEMO study impact dialysis practice?
|
Semin Dial
|
2003
|
0.75
|
|
141
|
Introduction.
|
Kidney Int Suppl
|
2002
|
0.75
|
|
142
|
Ionic dialysance allows an adequate estimate of urea distribution volume in hemodialysis patients.
|
Kidney Int
|
2004
|
0.75
|